Last updated: April 25, 2026
Revlimid is lenalidomide, a cancer therapy that is primarily supplied under Celgene/Bristol Myers Squibb (BMS) ownership. Commercial supply is dominated by BMS through its branded channel, while authorized generic and “authorized distributor” supply chains depend on region, regulatory authorization, and the specific marketing authorization holder.
What is Revlimid and who owns it?
Revlimid is the branded form of lenalidomide. Ownership and marketing responsibility for the Revlimid brand sit with Bristol Myers Squibb (BMS), following Celgene’s acquisition by BMS.
Key product identifiers
| Item |
Value |
| Drug |
Revlimid (lenalidomide) |
| Active ingredient |
Lenalidomide (IMiD class) |
| Brand owner/marketer (US) |
Bristol Myers Squibb |
Who are the suppliers (manufacturers) behind Revlimid?
Revlimid supply is not best described as a single “supplier list” because manufacturing and distribution can vary by:
- Region (US vs EU vs other markets)
- Presentation (capsule strengths)
- Regulatory authorization and labeling
- Contract manufacturing vs proprietary manufacturing
In practice, the supply chain for branded Revlimid is anchored by BMS (brand marketer) and executed by BMS and its manufacturing network (including contract manufacturing for some dosage forms). Where local labeling or regulatory filings list manufacturing sites, those sites function as the practical “suppliers” for the finished product.
What does the supply chain look like in practice?
For commercial sourcing, businesses typically map “suppliers” into two tiers:
Tier 1: Brand marketer / branded product supply
- Bristol Myers Squibb supplies Revlimid in its labeled branded channel.
Tier 2: Manufacturing sites and finished-dose packaging
- BMS-manufactured product and/or product produced through BMS-controlled manufacturing partners where the finished product is packaged and released for sale.
Do authorized generics exist, and who supplies them?
Yes. Lenalidomide’s market includes branded and generic products depending on jurisdiction and patent posture. In markets where generics are authorized, the effective “supplier set” changes to the local authorized manufacturers and marketing authorization holders for the generic equivalent.
For business procurement, the “supplier” question becomes:
- Is the buyer procuring Revlimid (BMS branded) or a generic lenalidomide?
- What region governs authorization and labeling?
How to interpret “suppliers for Revlimid” for procurement
For procurement and vendor qualification, treat “supplier” as one of the following operational roles:
- Marketing authorization holder / brand owner channel (for Revlimid): BMS
- Finished dose manufacturer / packager: BMS network and/or contract manufacturing plants listed on the product label and regional regulatory dossier
- Wholesale distributor: depends on the buyer’s country and distribution permissions; these are not the drug manufacturer but the sales channel
US procurement reality: branded supply is BMS-led
If the requirement is explicitly Revlimid (not “lenalidomide”), the supply source is the branded channel under BMS. Any downstream distributors that sell to wholesalers or pharmacies operate as distribution partners, not origin manufacturers.
EU procurement reality: site-specific labeling
In the EU, supplier identity for the finished product often appears in:
- Product labeling
- National competent authority regulatory documents
- EMA registration data and product information documents for the specific marketing authorization
This is where “supplier” maps to the listed manufacturing site(s) and release testing/packaging sites.
Key decision point for vendor lists
A supplier list can be either:
- BMS brand channel (Revlimid only), or
- Generic lenalidomide market (multiple authorized manufacturers)
Without specifying region and whether the purchase is branded Revlimid versus generic lenalidomide, a single authoritative supplier roster cannot be constructed.
Key Takeaways
- Revlimid (lenalidomide) is supplied through Bristol Myers Squibb’s branded channel.
- “Supplier” at procurement level typically resolves to BMS (brand marketer) plus BMS-controlled manufacturing and packaging/release sites that vary by region and product presentation.
- If the procurement is for generic lenalidomide, the supplier set expands to multiple authorized marketing holders and manufacturers by country.
FAQs
1) Who supplies Revlimid brand product?
Bristol Myers Squibb supplies Revlimid through its branded channel.
2) Are contract manufacturers involved in Revlimid production?
Yes, Revlimid supply can involve BMS-controlled manufacturing networks, including contract manufacturing and packaging sites, depending on region and dosage form.
3) Do wholesalers count as “suppliers” for Revlimid?
Wholesalers are distribution channel sellers, not the manufacturer of the active finished dose; procurement supplier lists often distinguish manufacturers from distributors.
4) Are there generic suppliers for lenalidomide?
Yes. Where generics are authorized in a jurisdiction, multiple manufacturers supply generic lenalidomide products, changing the supplier roster versus branded Revlimid.
5) Does supplier identity change by country?
Yes. Finished product labeling and regulatory authorizations can list different manufacturing and release sites across regions.
Cited Sources (APA)
[1] Bristol Myers Squibb. (n.d.). Revlimid (lenalidomide) prescribing information / product information.
[2] European Medicines Agency. (n.d.). Revlimid: EPAR and product information.
